D. DeGoey

发表

Desymmetrization of pibrentasvir for efficient prodrug synthesis†

J. Randolph, Jan E. Waters, E. Voight, 2021, Chemical science.

Antiviral Drug Discovery for the Treatment of COVID-19 Infections

Elizabeth L Noey, J. Seagal, W. Kati, 2022, Viruses.

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir , an Inhibitor of Hepatitis C Virus NS 5 A

A. Molla, T. Pilot‐Matias, T. Reisch, 2015 .

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

A. Molla, T. Pilot‐Matias, T. Reisch, 2014, Antimicrobial Agents and Chemotherapy.

Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

K. Longenecker, A. C. Krueger, A. Molla, 2013, Bioorganic & medicinal chemistry letters.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

A. Molla, D. Kempf, H. Mo, 2006, Bioorganic & Medicinal Chemistry.

Total synthesis and antifungal evaluation of cyclic aminohexapeptides.

Hui-ju Chen, Sheela A. Thomas, J. Plattner, 2000, Bioorganic & medicinal chemistry.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

A. C. Krueger, A. Molla, T. Pilot‐Matias, 2014, Journal of medicinal chemistry.

Enantioselective synthesis of antiinfluenza compound A-315675.

D. Kempf, Hui-ju Chen, L. L. Klein, 2002, The Journal of organic chemistry.

Preparation and antibacterial activity of pyridopyridone analogs : C-1 modifications

Sheela A. Thomas, L. L. Klein, P. Lartey, 1997 .

Desymmetrization of pibrentasvir for efficient prodrug synthesis†

J. Randolph, Jan E. Waters, E. Voight, 2021, Chemical science.

Peptidomimetic inhibitors of HIV protease.

J. Randolph, David A DeGoey, John T Randolph, 2004, Current topics in medicinal chemistry.

Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.

H. Mo, D. Kempf, K. Marsh, 2006, Bioorganic & Medicinal Chemistry.

HCV: The Journey from Discovery to a Cure: Volume II

C. Coburn, G. Dore, M. Sofia, 2019, Topics in Medicinal Chemistry.

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.

A. Molla, D. Kempf, T. Pilot‐Matias, 2013, Bioorganic & medicinal chemistry letters.

Prodrug Strategies to Improve the Solubility of HCV NS5A Inhibitor Pibrentasvir (ABT-530).

Brice E. Uno, J. Randolph, Deanne F. Stolarik, 2020, Journal of medicinal chemistry.

Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic Behavior.

Ahmad Y. Sheikh, Richard S. Hong, R. Henry, 2021, Journal of the American Chemical Society.

Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.

M. Wendt, Hui-ju Chen, Michael D Wendt, 2017, Journal of medicinal chemistry.

Drug Discovery Beyond the Rule of Five

David A. Degoey, Philip B. Cox, Philip B Cox, 2021 .

Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.

J. Randolph, Hui-ju Chen, Deanne F. Stolarik, 2020, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.

J. Randolph, R. Henry, Hui-ju Chen, 2019, Bioorganic & medicinal chemistry.

Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742

A. Molla, D. Kempf, L. L. Klein, 2008, Antimicrobial Agents and Chemotherapy.

Enantioselective Synthesis of Antiinfluenza Compound A-315675 (I).

D. Kempf, Hui-ju Chen, L. L. Klein, 2002 .

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

V. Stoll, A. Molla, D. Kempf, 2009, Journal of medicinal chemistry.

Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

A. Molla, D. Kempf, K. Marsh, 2009, Journal of medicinal chemistry.

HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments

J. Randolph, W. Kati, R. Wagner, 2019, Topics in Medicinal Chemistry.

Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro, and Preclinical Models.

B. Hosmane, S. Doktor, J. C. Kalvass, 2021, Journal of medicinal chemistry.

Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia

J. Waring, D. Kempf, J. Randolph, 2010, Archives of Toxicology.

Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain.

G. Gintant, R. Gum, T. Neelands, 2022, Bioorganic & medicinal chemistry.

Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.

R. Gum, T. Neelands, M. Kort, 2016, Journal of medicinal chemistry.

KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels

M. Gopalakrishnan, C. Surowy, P. Honore, 2011, Journal of Neuroscience Methods.

Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors

J. Waring, D. Kempf, J. Randolph, 2006, Antimicrobial Agents and Chemotherapy.